

## ABT-925 fumarate dihydrate

### Chemical Properties


CAS No. : 1160247-85-7

Formula: C<sub>24</sub>H<sub>35</sub>F<sub>3</sub>N<sub>6</sub>O<sub>7</sub>S

Molecular Weight: 608.63

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



### Biological Description

Description	ABT-925 is a selective dopamine D3 receptor (DRD3) antagonist with an in vitro affinity approximately 100 times higher for dopamine D3 receptors than for D2 receptors.
Targets(IC50)	Others

### Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.643 mL	8.2152 mL	16.4303 mL
5 mM	0.3286 mL	1.643 mL	3.2861 mL
10 mM	0.1643 mL	0.8215 mL	1.643 mL
50 mM	0.0329 mL	0.1643 mL	0.3286 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Pich EM, Collo G. Pharmacological targeting of dopamine D3 receptors: Possible clinical applications of selective drugs. *Eur Neuropsychopharmacol*. 2015 Sep;25(9):1437-47. doi: 10.1016/j.euroneuro.2015.07.012. Epub 2015 Jul 21. PubMed PMID: 26298833.

Bhathena A, Wang Y, Kraft JB, Idler KB, Abel SJ, Holley-Shanks RR, Robieson WZ, Spear B, Redden L, Katz DA. Association of dopamine-related genetic loci to dopamine D3 receptor antagonist ABT-925 clinical response. *Transl Psychiatry*. 2013 Apr 9;3:e245. doi: 10.1038/tp.2013.22. PubMed PMID: 23571810; PubMed Central PMCID: PMC3641409.

Gross G, Wicke K, Drescher KU. Dopamine D<sub>3</sub> receptor antagonism--still a therapeutic option for the treatment of schizophrenia. *Naunyn Schmiedebergs Arch Pharmacol*. 2013 Feb;386(2):155-66. doi: 10.1007/s00210-012-0806-3. Epub 2012 Nov 6. Review. PubMed PMID: 23128852.

Redden L, Rendenbach-Mueller B, Abi-Saab WM, Katz DA, Goenjian A, Robieson WZ, Wang Y, Goss SL, Greco N 4th, Saltarelli MD. A double-blind, randomized, placebo-controlled study of the dopamine D<sub>3</sub> receptor antagonist ABT-925 in patients with acute schizophrenia. *J Clin Psychopharmacol*. 2011 Apr;31(2):221-5. doi: 10.1097/JCP.0b013e31820e4818. PubMed PMID: 21346607.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481